In reaction to disappointing earnings/guidance:
- AEO -8.8%, JRJC -5.9%, EEFT -5.4%, NTNX -3.6%, TOUR -3.6%, ANFI -2.9%, FSC -2.5%, (also approved a new common stock repurchase program)
- ADSK -1.7%, MCHP -1%, (increases guidance for non-GAAP net sales & non-GAAP EPS for 3Q17), GWRE -0.8%
- ARWR -61.3% (will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle)
- CERC -46% (announces top-line clinical results from its major depressive disorder Phase 2 clinical trial of adjunctive treatment of CERC-301; study misses primary endpoint)
- CMRE -13.7% (upsizes offering by 1 mln shares prices 12 mln shares of common stock at $6.00)
- FBP -8.9% (announces that Thomas H. Lee Partners and Oaktree commence secondary offering of 18 million shares)
- FPI -6.7% (commences 3.1 mln common stock offering)
- EVH -4.5% (Evolent Health to offer $110 mln of convertible senior notes due 2021)
- OCUL -3.4% (enters into controlled equity offering sales agreement to offer and sell shares of its common stock having an aggregate offering price of up to $40 mln)
- NLNK -2.3% (enters into Controlled Equity Offering Sales Agreement to offer and sell shares of common stock having an aggregate offering price of up to $40 mln)
- FTD -2.3% (ticking lower; CFO Becky Sheehan is leaving on Dec 31, 2016 to pursue other opportunities)
- RBS -2.2% (fails BOE stress test) .
- ABAX -0.8% (downgraded to Buy at Northcoast)
- FFIV -0.6% (downgraded to Mkt Perform from Outperform at Bernstein)
In reaction to strong earnings/guidance:
- CSBR +15.2%, (thinly traded; also details new strategic emphasis), SPLK +7.2%
- OII +4.7%, (provides updated forecast ahead of tomorrow's presentation at the Jefferies 2016 Energy Conference ), DL+4.1%, OOMA +2.6%
- CRC +31.5%, DNR +14.1%, SGY +12.7%, SDRL +11.8%, WTI +11.1%, OAS +10.5%, SN +10.3%, ESV +10.2%, WLL+10%, TNP +9.6%, BTE +9%
- NE +8.6%, MRO +8%, WFT +7.6%, PBR +7.5%, CHK +7.5%, DVN +7.4%, RIG +6.4%, APC +6.2%, APA +5.9%, GTE+5.8%, HAL +5%, COP +4.7%, SU +4.6%
- SCON +67.5% (awarded $4.5 mln DOE contract to improve HTS Wire for Next Generation Electric Machines program)
- CLSN +30.7% (announces the Data Monitoring Committee of its Phase III clinical study of ThermoDox)
- WING +4.6% (will replace Papa John's International in the S&P SmallCap 600)
- KMI +4% ( Government of Canada has granted approval for the Trans Mountain Expansion Project)
- GPRO +4% (announces 'solid' holiday quarter sell-thru in the U.S. for its new HERO5 cameras, unveils company restructuring, President Tony Bates to depart by year-end)
- SKLN +2.8% ( indicated lower after filing 424B5 for offering by investors)
- UL +2.7% (provides objectives/targets for 2017-2019 at its investor seminar; intends to raise cash conversion to 90% (up from 80% current)
- BLDP +1.6% (Ballard Power signs supply agreement with Solaris; receives initial order for 10 fuel cell modules for trolley buses )
- PPS +1% (higher on S&P index change news - Mid-America Apartment Communities is acquiring Post Properties in a deal expected to be completed on December 1 pending final conditions)
- PZZA +0.7% (will replace Post Properties in the S&P MidCap 400)
- XTNT +12.2% (initiated with a Buy at Aegis Capital; tgt $3.50)
- HOME +3.3% (upgraded to Buy at Goldman)
- TCK +1.3% (upgraded to Hold at Berenberg)
Early premarket gappers
Gapping up: SCON +62.5%, CSBR +13.1%, BTE +11.2%, ESV +11%, DNR +10.6%, SN +10.3%, SDRL +9.8%, GTE +9.6%, TNP +9.6%, OAS +9.2%, WLL +9.1%, NE +9%, WTI +7.8%, MRO +6.7%, PBR +6.6%, SPLK +6.5%, CHK +6.3%, RIG +5.8%, WFT +5.6%, DVN +5.3%, APC +5.2%, APA +4.9%, WING +4.7%, SU +4.6%, COP +4.6%, HAL +4.6%, DL +4.1%, KMI +3.9%, OOMA +2.6%, SKLN +2.1%, BLDP +1.6%, PPS +1%
Gapping down: ARWR -63.1%, CERC -46.8%, CMRE -13.1%, FBP -7.4%, EVH -7.2%, FPI -6%, JRJC -5.9%, NTNX -4.1%, ANFI -2.9%, NLNK -2.3%, FTD -2.3%, ADSK -2%, FSC -1%, GWRE -0.8%
S&P 500 Forecasts
Price Target (2017 YE): 2,400
EPS (2017): $128
EPS (2016): $120
VIX (Average): 16-18
Key Drivers
US business cycle entered new intra-cycle expansion
Improving growth, sentiment, liquidity, inflation data
Resilient economic growth with rising inflation
Real GDP growth 2.0% y/y; Core CPI 2.3% y/y
From disinflation to reflation
Inflation expectations moving higher
Improving fundamentals
Expect 7-8% EPS upside on stronger top line in 2017
New US administration mostly pro-growth
Could add up to ~$20 to S&P EPS over multiple years
Equities possess attractive cross-asset valuation
4.3% Equity (Div + Buyback) yld vs 2.3% Bond yld
Key Risks
Higher volatility likely and elevated equity tail risks
Resulting in periods of volatile selloffs (e.g., Jan ’16)
Stronger USD, pressuring profits and margins
2% Δ in USD TWI = ~ -1% Δ in S&P500 EPS
Rising bond yields, higher borrowing costs
100bp rise in yields = ~$1.30 hit to ’17 S&P500 EPS
High equity multiple at ~17x P/E
Earnings growth support needed
Geopolitical risks
Brexit, FR/GR elections, IT ref, Middle East
New US administration political uncertainty
Trade protectionism disrupting global economy